Cronos Group Inc. — Regulatory Filings 2018

Sep 4, 2018

6-K 1 d618057d6k.htm 6-K 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Section 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of: September, 2018

Commission File Number: 001-38403

CRONOS GROUP INC.

(Name of registrant)

720 King Street W., Suite 320

Toronto, Ontario

M5V 2T3

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☐ Form 40-F ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CRONOS GROUP INC. — By:	/s/ Michael Gorenstein
Name:	Michael Gorenstein
Title:	President and Chief Executive Officer

EXHIBIT INDEX

| Exhibit | Description of
Exhibit |
| --- | --- |
| 99.1 | News release dated September 4, 2018 – “Cronos Group and Ginkgo Bioworks Announce a Landmark Partnership to
Produce Cultured Cannabinoids” |
| 99.2 | The material change report of Cronos Group Inc. dated September 4, 2018 in respect of the announcement of the
collaboration and license agreement with Ginkgo Bioworks, Inc. |
| 99.3 | Collaboration and License Agreement, dated as of September 1, 2018, by and between Ginkgo Bioworks, Inc. and Cronos
Group Inc. |